Literature DB >> 18687642

Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma.

Bruce D Cheson1, John P Leonard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18687642     DOI： 10.1056/NEJMra0708875

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  130 in total

1.  TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas.

Authors:  Jinsheng Weng; Seema Rawal; Fuliang Chu; Hyun Jun Park; Rakesh Sharma; David A Delgado; Luis Fayad; Michelle Fanale; Jorge Romaguera; Amber Luong; Larry W Kwak; Sattva S Neelapu
Journal:  Blood       Date:  2012-05-29       Impact factor: 22.113

2.  The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas.

Authors:  Maximillian Rosario; Bai Liu; Lin Kong; Lynne I Collins; Stephanie E Schneider; Xiaoyue Chen; Kaiping Han; Emily K Jeng; Peter R Rhode; Jeffrey W Leong; Timothy Schappe; Brea A Jewell; Catherine R Keppel; Keval Shah; Brian Hess; Rizwan Romee; David R Piwnica-Worms; Amanda F Cashen; Nancy L Bartlett; Hing C Wong; Todd A Fehniger
Journal:  Clin Cancer Res       Date:  2015-09-30       Impact factor: 12.531

3.  Evaluation of AKT phosphorylation and PTEN loss and their correlation with the resistance of rituximab in DLBCL.

Authors:  Yihui Ma; Pengyu Zhang; Yi Gao; Huijie Fan; Mingzhi Zhang; Jingjing Wu
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

4.  Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma.

Authors:  Thomas E Witzig; Michael B Tomblyn; Jamal G Misleh; Ebenezer A Kio; Robert M Sharkey; William A Wegener; David M Goldenberg
Journal:  Haematologica       Date:  2014-08-22       Impact factor: 9.941

5.  Establishment of a novel CD20 negative mature B-cell line, WILL2, from a CD20 positive diffuse large B-cell lymphoma patient treated with rituximab.

Authors:  Takashi Sonoki; Yaqiong Li; Setsuko Miyanishi; Hirokazu Nakamine; Nobuyoshi Hanaoka; Hiroshi Matsuoka; Ichiro Mori; Hideki Nakakuma
Journal:  Int J Hematol       Date:  2009-03-31       Impact factor: 2.490

Review 6.  Advances in the use of biologic agents for the treatment of systemic vasculitis.

Authors:  Sharon A Chung; Philip Seo
Journal:  Curr Opin Rheumatol       Date:  2009-01       Impact factor: 5.006

7.  Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era.

Authors:  Grzegorz S Nowakowski; Matthew J Maurer; Thomas M Habermann; Stephen M Ansell; William R Macon; Kay M Ristow; Cristine Allmer; Susan L Slager; Thomas E Witzig; James R Cerhan
Journal:  J Clin Oncol       Date:  2009-12-14       Impact factor: 44.544

Review 8.  Antibody-based therapeutics for the treatment of human B cell malignancies.

Authors:  Sivasubramanian Baskar; Natarajan Muthusamy
Journal:  Curr Allergy Asthma Rep       Date:  2013-02       Impact factor: 4.806

9.  Semiquantitative assessment of the microdistribution of fluorescence-labeled monoclonal antibody in small peritoneal disseminations of ovarian cancer.

Authors:  Nobuyuki Kosaka; Mikako Ogawa; David S Paik; Chang H Paik; Peter L Choyke; Hisataka Kobayashi
Journal:  Cancer Sci       Date:  2009-10-31       Impact factor: 6.716

Review 10.  Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders.

Authors:  M C Levesque
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.